Display options
Cite
Hu X, Zhang YA, Chen B, et al. Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGD. Int Immunopharmacol. 2021;102:108348doi: 10.1016/j.intimp.2021.108348.
Hu, X., Zhang, Y. A., Chen, B., Jin, Z., Lin, M. L., Li, M., Mei, H. X., Lu, J. C., Gong, Y. Q., Jin, S. W., & Zheng, S. X. (2022). Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGD. International immunopharmacology, 102108348. https://doi.org/10.1016/j.intimp.2021.108348
Hu, Xin, et al. "Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGD." International immunopharmacology vol. 102 (2022): 108348. doi: https://doi.org/10.1016/j.intimp.2021.108348
Hu X, Zhang YA, Chen B, Jin Z, Lin ML, Li M, Mei HX, Lu JC, Gong YQ, Jin SW, Zheng SX. Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGD. Int Immunopharmacol. 2022 Jan;102:108348. doi: 10.1016/j.intimp.2021.108348. Epub 2021 Nov 10. PMID: 34920958; PMCID: PMC8578004.
Copy Download .nbib Format: NLM
Share it on

Int Immunopharmacol. 2022 Jan;102:108348. doi: 10.1016/j.intimp.2021.108348. Epub 2021 Nov 10.

Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGD.

International immunopharmacology

Xin Hu, Ye-An Zhang, Ben Chen, Zi Jin, Mei-Lin Lin, Ming Li, Hong-Xia Mei, Jia-Chao Lu, Yu-Qiang Gong, Sheng-Wei Jin, Sheng-Xing Zheng

Affiliations

  1. Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, People's Republic of China.
  2. Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, People's Republic of China. Electronic address: [email protected].
  3. Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, People's Republic of China. Electronic address: [email protected].
  4. Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, People's Republic of China. Electronic address: [email protected].

PMID: 34920958 PMCID: PMC8578004 DOI: 10.1016/j.intimp.2021.108348

Abstract

PURPOSE: Acute respiratory distress syndrome (ARDS) is characterized by uncontrollable inflammation. Cyclooxygenase-2(COX-2) and its metabolite prostaglandins are known to promote the inflammatory resolution of ARDS. Recently, a newly discovered endogenous lipid mediator, Protectin DX (PDX), was also shown to mediate the resolution of inflammation. However, the regulatory of PDX on the pro-resolving COX-2 in ARDS remains unknown.

MATERIAL AND METHODS: PDX (5 μg/kg) was injected into rats intravenously 12 h after the lipopolysaccharide (LPS, 3 mg/kg) challenge. Primary rat lung fibroblasts were incubated with LPS (1 μg/ml) and/or PDX (100 nM). Lung pathological changes examined using H&E staining. Protein levels of COX-2, PGDS and PGES were evaluated using western blot. Inflammatory cytokines were tested by qPCR, and the concentration of prostaglandins measured by using ELISA.

RESULTS: Our study revealed that, COX-2 and L-PGDS has biphasic activation characteristics that LPS could induce induced by LPS both in vivo and in vitro.. The secondary peak of COX-2, L-PGDS-PGD

CONCLUSION: PDX promoted the resolution of inflammation of ARDS model via enhancing the expression of secondary peak of COX-2/L-PGDS-PGD

Copyright © 2021. Published by Elsevier B.V.

Keywords: Acute respiratory distress syndrome; Cyclooxygenase-2; Inflammatory resolution; Lipocalin-type prostaglandin D synthase; Protectin DX

References

  1. Nat Rev Drug Discov. 2004 May;3(5):401-16 - PubMed
  2. Trends Mol Med. 2006 Apr;12(4):148-58 - PubMed
  3. Am J Pathol. 1997 Aug;151(2):317-22 - PubMed
  4. Annu Rev Immunol. 2007;25:101-37 - PubMed
  5. Nat Med. 1999 Jun;5(6):698-701 - PubMed
  6. Transplantation. 2001 Jan 27;71(2):337-9 - PubMed
  7. Respir Physiol Neurobiol. 2014 Sep 15;201:7-14 - PubMed
  8. J Cell Physiol. 2008 Nov;217(2):433-41 - PubMed
  9. Int J Biochem Cell Biol. 2006;38(10):1654-61 - PubMed
  10. J Cell Mol Med. 2020 Dec;24(23):14001-14012 - PubMed
  11. J Immunol. 2014 Apr 15;192(8):3765-77 - PubMed
  12. Stem Cell Res Ther. 2016 Apr 29;7(1):66 - PubMed
  13. Nat Rev Dis Primers. 2019 Mar 14;5(1):18 - PubMed
  14. J Immunol. 2017 Aug 9;: - PubMed
  15. Inflammopharmacology. 2005;12(5-6):473-6; discussion 477-80 - PubMed
  16. Mediators Inflamm. 2012;2012:696897 - PubMed
  17. Pharmacol Rev. 2007 Sep;59(3):207-24 - PubMed
  18. J Cell Mol Med. 2020 Sep;24(18):10604-10614 - PubMed
  19. J Pathol. 2019 Jul;248(3):280-290 - PubMed
  20. J Immunol. 2005 Apr 15;174(8):5033-9 - PubMed
  21. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20979-84 - PubMed
  22. Br J Pharmacol. 2008 Mar;153 Suppl 1:S200-15 - PubMed
  23. Semin Respir Crit Care Med. 2019 Feb;40(1):31-39 - PubMed
  24. N Engl J Med. 2000 May 4;342(18):1334-49 - PubMed
  25. Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000 - PubMed
  26. FASEB J. 2017 Apr;31(4):1273-1288 - PubMed
  27. Front Pharmacol. 2019 Jan 17;9:1582 - PubMed
  28. Am J Respir Cell Mol Biol. 2013 May;48(5):610-8 - PubMed
  29. N Engl J Med. 1997 Mar 27;336(13):912-8 - PubMed
  30. Intensive Care Med. 2004 Jan;30(1):51-61 - PubMed
  31. Mediators Inflamm. 2013;2013:964012 - PubMed
  32. Br J Pharmacol. 2015 Sep;172(18):4454-4468 - PubMed
  33. Br J Pharmacol. 2008 Mar;153 Suppl 1:S241-6 - PubMed
  34. Exp Mol Med. 2018 Apr 27;50(4):1-13 - PubMed
  35. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5205-10 - PubMed
  36. J Org Chem. 2019 Jan 18;84(2):495-505 - PubMed
  37. Mediators Inflamm. 2011;2011:745340 - PubMed
  38. Future Med Chem. 2011 Nov;3(15):1909-34 - PubMed

Publication Types